MedPath

Semaglutide Shows Promise in Reducing Opioid Overdose Risk in Type 2 Diabetes Patients

10 months ago2 min read

Key Insights

  • A recent study suggests semaglutide, used for type 2 diabetes and weight loss, may significantly reduce the risk of opioid overdose in patients with both conditions.

  • The study compared semaglutide to other antidiabetic medications, finding a 42% to 68% lower overdose risk in the semaglutide group over a one-year follow-up.

  • Researchers emphasize the need for further randomized clinical trials to validate these findings and explore the mechanisms behind semaglutide's potential benefits.

A new study indicates that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) commonly used to treat type 2 diabetes and obesity, may significantly reduce the risk of opioid overdose in patients with both type 2 diabetes and opioid use disorder (OUD). The research, utilizing electronic health records from the TriNetX Analytics Platform, compared semaglutide to other antidiabetic medications, including other GLP-1 RAs, insulin, and metformin.

Semaglutide's Impact on Opioid Overdose Risk

The study, published in JAMA Network Open, employed a cohort design to emulate a target trial, evaluating patients for up to a year after being prescribed semaglutide or other antidiabetic medications. Propensity-score matching was used to adjust for differences in baseline characteristics. The primary outcome was opioid overdose, with hazard ratios (HRs) calculated to assess risk reduction. The results demonstrated that semaglutide was associated with a significantly lower risk of opioid overdose compared to other GLP-1 RAs like liraglutide and dulaglutide. The hazard ratios ranged from 0.32 to 0.58, indicating a 42% to 68% lower risk of overdose in the semaglutide group during the one-year follow-up period.

Expert Commentary and Context

Rong Xu, research team leader and director of the Case Western Reserve University School of Medicine Center for AI in Drug Discovery, emphasized the importance of alternative medications for OUD, stating, "Not everyone receives or responds to them. As a result, alternative medications to help people treat opioid use disorder and prevent overdosing are crucial. Therefore, our findings suggest that it is important to continue studying semaglutide as a possible new treatment for combating this terrible epidemic."

Semaglutide's Expanding Therapeutic Potential

Semaglutide, the active ingredient in Novo Nordisk’s Wegovy and Ozempic, has shown promise in various indications beyond diabetes and weight loss, including kidney failure, obesity, and heart failure. The FDA recently approved Wegovy for reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who are also obese or overweight.

Study Limitations and Future Directions

The authors acknowledge that the study's observational design may introduce biases and that further research, including randomized clinical trials, is needed to validate these results and explore the underlying mechanisms of semaglutide's effects on opioid use. Despite these limitations, the findings suggest that semaglutide could have therapeutic potential in reducing opioid overdose risk in patients with comorbid type 2 diabetes and OUD.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.